Press Release Headlines

Kibow Biotech Showcases Renadyl™ During Kidney Week ASN Convention in Atlanta Nov. 7-9

Company will present results from recent clinical trial, safety data and benefits of the probiotic dietary supplement for kidney health

NEWTOWN SQUARE, Pa., Nov. 4, 2013 /PRNewswire/ — A major annual event of the American Society of Nephrology (ASN) – The Kidney Week – is to be held Nov. 5-10 in Atlanta, GA. Kibow Biotech, Inc. is pleased to announce their continued participation as an exhibitor at this event. In addition, the company will also be presenting three posters in joint authorship with the clinical nephrologists from Downstate Medical Center, State University of New York (SUNY), Brooklyn, NY.  Data from their recently completed clinical trial of Renadyl™ in patients undergoing routine dialysis confirm earlier positive results, safety, as well as some additional benefits in counteracting some specific uremia-related biomarkers. Improved quality of life (QOL), already observed in the previously published pilot-scale study for kidney failure patients, was also reconfirmed by the new data.

Renadyl™, a probiotic dietary supplement, is currently sold via Kibow's own online store ( or This probiotic dietary supplement is known for its ability to target and help reduce the buildup of uremic toxins in the body, thus helping to maintain healthy kidney function, via Kibow's Uremic Toxin Reduction Technology. The probiotic microbial strains used in the product formulation are "Generally Recognized as Safe" (GRAS status), according to the regulations of U.S. FDA.

About Kibow Biotech

Founded in 1997, Kibow Biotech specializes in research and development of probiotic dietary supplements. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health. The Company's flagship product, Renadyl™, is currently marketed in the US and Canada, and will progressively be made available worldwide, according to individual countries' governmental rules and regulatory authorities.

About Uremic Toxin Reduction Technology

Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for CKD patients) and Azodyl™ (veterinary formulation licensed to Vetoquinol SA) consist of a combination of three specific probiotic microbial strains. The results of a randomized, double-blind, crossover, pilot scale clinical trial completed in 2010 provided encouraging preliminary evidence that the Company's technology could be effective when the formulation is taken together with the standard therapy in accordance with individual patient's condition.

Forward-looking statements

This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Renadyl™, for kidney health in the USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl™ will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Renadyl™ may not prove to be safe or show evidence of clinical activity in each and every individuals due to various environmental or genetic factors. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop dietary supplements using the technologies of the Company, whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Investor &  Media Contact:

Natarajan Ranganathan, Ph.D.,
(610) 353 5130) or Email